Altered levels and molecular forms of granzyme K in plasma from septic patients

Shock

Volumn 27, Issue 5, 2007, Pages 488-493

  Rucevic, Marijana ^a   Fast, Loren D ^a   Jay, Gregory D ^a   Trespalcios, Flor M ^a   Sucov, Andrew ^a   Siryaporn, Edward ^b   Lim, Yow Pin ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b ProThera Biologics   (United States)

Author keywords

Biomarker; Granzyme K; Granzymes; Inter alpha inhibitor proteins; Sepsis; Serine protease

Indexed keywords

GRANZYME K; RECOMBINANT ENZYME; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; ISOENZYME ANALYSIS; PATHOPHYSIOLOGY; PROTEIN DETERMINATION; SEPSIS; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-GLOBULINS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANZYMES; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; MOLECULAR WEIGHT; SEPSIS;

EID: 34247262710     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000246905.24895.e5     Document Type: Article

References (28)

1. Carrigan SD, Scott G, Tabrizian M: Toward resolving the challenges of sepsis diagnosis. Clin Chem 50:1301-1314, 2004.
2. Marshall JC, Vincent JL, Fink MP, Cook DJ, Rubenfeld G, Foster D, Fisher CJ Jr, Faist E, Reinhart K: Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Canada, 2000. Crit Care Med 31:1560-1567, 2002.
3. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377, 2001.
4. Zeerleder S, Hack CE, Caliezi C, van Mierlo G, Eerenberg-Belmer A, Wolbink A, Wuillenmin WA: Activated cytotoxic T cells and NK cells in severe sepsis and septic shock and their role in multiple organ dysfunction. Clin Immunol 116:158-165, 2005.
5. van Griensven M, Dalhweid M, Giannoudis PV, Wittwer T, Böttcher F, Breddin M, Pape H: Dehydroepiandrosterone (DHEA) modulates the activity and the expression of lymphocyte subpopulations induced by cecal ligation and puncture. Shock 18:445-449, 2002.
6. van Griensven M, Probst C, Muller K, Hoevel P, Pape HC: Leukocyte-endothelial interactions via ICAM-1 are detrimental in polymicrobial sepsis. Shock 25:254-259, 2006.
7. Tak PP, Spaeny-Dekking L, Kraan MC, Breedveld FC, Froelich CJ, Hack CE: The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 116:366-370, 1999.
8. Lauw FN, Simpson AJH, Hack CE, Prins JM, Wolbink AM, Chaowagul W, White NJ, Poll TVD: Soluble granzymes are released during human endotoxemia and in patients with severe infection due to gram-negative bacteria. J Infect Dis 182:206-213, 2000.
9. Masson D, Tschop J: Inhibition of lymphocyte protease granzyme A by antithrombin III. Mol Immunol 25:1283-1289, 1988.
10. Spaeny-Dekking EHE, Kamp A, Froelich C, Hack C: Extracellular granzyme A, complexed to proteoglycan, is protected against inactivation by protease inhibitors. Blood 95:1465-1472, 2000.
11. Tsuzuki S, Kokado Y, Satomi S, Yamasaki Y, Hirayasu H, Iwanaga T, Fushki T: Purification and identification of binding protein for pancreatic secretory trypsin inhibitor: a novel role of the inhibitor as an anti-granzyme A. Biochem J 372:227-233, 2003.
12. Lim YP, Bendelja K, Opal SM, Siryaporn E, Hixon DC, Palardy JE: Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis. J Infect Dis 188:919-926, 2003.
13. Baek WB, Brokat S, Padbury JF, Pinar H, Hixon DC, Lim YP: Inter-α inhibitor proteins in infants and decreased levels in neonatal sepsis. J Pediatr 143:11-15, 2003.
14. Wilharm E, Parry MAA, Friebel R, Tschesche H, Matschiner G, Sommerhoff CP, Dieter JE: Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma. J Biol Chem 274:27331-27337, 1999.
15. Hanna WL, Zhang X, Turbov J, Winkler U, Hudig D, Froelich CJ: Rapid purification of cationic granule proteases: application to human granzymes. Protein Expr Purif 4:398-404, 1993.
16. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970.
17. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, Murphy DJ, Lotring T, Damiano A, et al.: The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100:1619-1636, 1991.
18. Spaeny-Dekking EHA, Hanna WL, Wolbink AM, Wever PC, Kummer AJ, Swaak AJG, Middeldrop JM, Huisman HG, Froelich JC, Hack E: Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol 160:3610-3616, 1998.
19. Carrell RW, Lomas DA: Alpha1-antitrypsin deficiency - a model for conformational diseases. N Engl J Med 346:45-53, 2002.
20. Tremblay G, Wolbink A, Cormier Y, Hack C: Granzyme activity in the inflamed lung is not controlled by endogenous proteinase inhibitors. J Immunol 165:3966-3969, 2000.
21. Lomas DA, Mahadeva R: α1-Antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 110:1585-1590, 2002.
22. Morelle W, Capon C, Balduyck M, Sautiere P, Kouach M, Michalski C, Fournet B, Mizon J: Chondroitin sulphate covalently cross-links the three polypeptide chains of inter-alpha-trypsin inhibitor. Eur J Biochem 221:881-888, 1994.
23. Enghild JJ, Thogersen IB, Cheng F, Fransson LA, Roepstorff P, Rahbek-Nielsen H: Organization of the inter-alpha-inhibitor heavy chains on the chondroitin sulfate originating from Ser(10) of bikunin: posttranslational modification of IalphaI-derived bikunin. Biochemistry 38:11804-11813, 1999.
24. Martich G, Danner R, Ceska M, Suffredini A: Detection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 173:1021-1024, 1991.
25. Maring M, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, Jungbluth A, Wada H, Moore M, Williamson B, et al.: Characterization of tumor necrosis-factor deficient mice. Proc Natl Acad Sci U S A 94:8093-8098, 1997.
26. van der Poll T, Coyle S, Lowry S: Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL-1 receptor type II, IL-10, and IL-13. J Infect Dis 175:118-122, 1997.
27. Hanna J, Bechtel P, Zhai Y, Youssef F, McLachlan K, Mandelboim O: Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol 173:6547-6563, 2004.
28. Bade B, Lohrmann J, ten Brinke A, Wolbink AM, Wolbink GJ, ten Berge IJM Jr, Virchow JC, Luttmann W, Hack CE: Detection of soluble human granzyme K in vitro and in vivo. Eur J Immunol 35:2940-2948, 2005.